A double cure: Omenn syndrome and b thalassaemia successfully treated with mismatched unrelated donor transplantation
Omenn syndrome (OS) describes forms of SCID with additional characteristic features, including erythroderma, hepatosplenomegaly and lymphadenopathy. 1 A variety of genetic defects responsible for lymphocyte or thymic development can give rise to OS, with mutations in genes responsible for V(D)J recombination during T-and B-cell development, such as the recombinase-activating genes (RAG1 and RAG2) being the best characterised. 2 Here we describe an infant suffering with OS as well as b thalassaemia, who was successfully cured of both conditions by mismatched unrelated donor hematopoietic SCT following reduced intensity conditioning.
The infant was born at term after an uneventful pregnancy to consanguineous Asian parents, known to be b-thalassaemia carriers. Routine postnatal screening at 5 days of age detected 100% fetal Hb consistent with bthalassaemia major, and this was confirmed on subsequent genetic analysis (homozygous for b thalassaemia with codon 8/9 ( þ G) mutation). Delayed separation of the umbilical cord stump, failure to thrive and an erythrodermatous skin rash was investigated further at the age of 2 months. Immunological investigations revealed absent B cells and although her CD3 T-cell count was raised (10.2 Â 10 9 /L), these cells were associated with an abnormal phenotype, with a predominance of activated CD4 cells, and they failed to respond to mitogenic stimulation in vitro. In association with low serum Igs (IgG 2.63 g/L, IgA o0.05 g/L, IgM 0.07 g/L) and eosinophilia, a clinical diagnosis of OS was made. Genetic analysis subsequently detected heterozygotic mutations of the recombinaseactivating gene-1 (RAG1), the gene most commonly associated with OS. The patient was hypertransfused to maintain Hb above 13 g/dL, but she did not require chelation therapy and did not develop the organ-specific co-morbidities often associated with thalassaemia in older patients. A single Ag (DRB1) mismatched unrelated donor was identified following registry searches. Sub-myeloablative conditioning with treosulphan (three daily doses of 12 g/m /kg. Stable 100% donor engraftment was achieved without significant GVHD. At 6 months after transplantation, the patient developed haemolytic anaemia, requiring red cell transfusions. The detection of red cell antibodies confirmed an immune-based mechanism and additional immunosuppression with prednisolone (2 mg/kg per day) and rituximab (four weekly doses of 375 mg/m 2 ) was required to control haemolysis. After withdrawal of immunosuppression, the patient went on to fully reconstitute her cellular immune compartment with normal lymphocyte subsets, including naive T-cell populations, good thymic output as determined by levels of T-cell receptor excision circles and diverse T-cell repertoire as characterised by T-cell receptor Vb spectratyping. At 2 years after her transplant, she has full donor chimaerism in all lineages, is transfusion independent, off all immunosuppression and no longer receiving Ig replacement therapy.
To our knowledge, this is the first description of a patient with both b-thalassaemia and RAG1 deficiency causing OS phenotype SCID. Reduced intensity conditioning for unrelated donor HSCT has been shown to be highly effective for the treatment of primary immunodeficiencies, with reduced procedure related mortality and improved overall survival. [3] [4] [5] However, the use of reduced intensity conditioning regimens and unrelated donors in b thalassaemia remains limited, with concerns about transplant-related morbidity and fears of graft rejection. 6, 7 Mostly, procedures are only undertaken in the matched family donor setting using conventional myeloablative conditioning. In this patient, the absence of host immunity because of SCID was undoubtedly advantageous, reducing the risk of graft rejection. Although infants with certain SCID disorders can be transplanted without conditioning, a T-cell permissive environment is required, and engraftment is usually restricted to the T-cell lineage. In OS, conditioning ensures eradication of recipient T-cell clones and facilitates multilineage engraftment. In this patient, conditioning with treosulphan and fludarabine was sufficient to ensure stable multilineage engraftment using a matched unrelated donor PBSC graft. The inclusion of alemtuzumab serotherapy helped to ensure that there was no significant GVHD despite a single Ag mismatch and a CD3 cell dose of 410 8 / kg. The development of immune mediated haemolytic anaemia, which followed a protracted course and required a significant period of immunosuppression. This is not unusual following allogeneic transplantation, but in OS there may be additional factors relating to thymic expression of autoimmune regulator (AIRE) gene. Previously, it has been reported that children with OS have reduced AIRE expression and this may contribute to the emergence of non-tolerant, autoreactive T-cells clones, which mediate the systemic disease seen in the condition. 8, 9 After transplantation, partially reduced AIRE expression may continue to effect thymic tolerance, and thereby increase the risk of immune-mediated complications. Fortunately, in this case, autoimmune complications were responsive to therapy and durable reconstitution of the entire haematopoietic compartment was secured. For patients with b thalassaemia, this case provides valuable evidence that unrelated donor stem cells can durably engraft without myeloablation if host cellular immunity is absent, and supports the use of lymphodepleting conditioning regimens.
